Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2016

View Archived Issues

Mymetics' HIV vaccine candidate shows promise in preclinical study

Ipsen describes novel melanocortin MC2 receptor antagonist for Cushing's disease

FDA grants fast track status for Carbavance

Immunogenicity and safety of MG-1109

Ariad initiates phase III trial of brigatinib in patients with ALK-positive NSCLC

Data reported from phase III study of surotomycin for CDAD

Altor BioScience and NCI partner to develop cancer immunotherapeutics

Encouraging results seen in phase II murepavadin study

Celgene exercises option to develop and commercialize Juno's CD19-directed drug candidates

Bayer Schering Pharma patents coagulation factor XIa and KLKB1 inhibitors

Araxes Pharma discloses RAS inhibitors

Gilead Sciences describes TBK1 and IKK-epsilon inhibitors

BTA-585 enters phase IIa trial for the treatment of RSV infections

Tetra Discovery Partners reports PDE4 inhibitors

Hydra Biosciences presents TRPA1 antagonists

GW Pharmaceuticals initiates phase III pivotal trial of Epidiolex in tuberous sclerosis complex

RedHill Biopharma starts phase II trial of Bekinda in patients with IBS-D

Enrollment open in phase I study of MIW-815 for advanced cancers

Hutchison MediPharma initiates first-in-human study of HMPL-689

Regeneron and Intellia sign CRISPR/Cas-based licensing and collaboration agreement

Cerecor awarded NIDA grant

Cardiac peptide proANP(31-67) beneficial in patients with congestive heart failure

Nordic Nanovector and PSI enter R&D agreement

FDA grants accelerated approval to Venclexta for relapsed/refractory CLL with 17p deletion

HalioDx and NanoString Technologies collaborate on gene expression assays in immuno-oncology

Molecular Stethoscope collaborates with academic and medical institutions on diagnostic development

Cancer metabolic imaging trial begins in U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...